1-20 of 41
Matthew Matasar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma

Paolo F. Caimi, Scott F Huntington, Sean Landrette, Sheryl M Gough, Vivian Dai, Bryan Jackson, Tinghui Yu, Juan Chavez, Sarah Tannenbaum-Dvir, Matthew Matasar
Journal: Blood
Blood (2024) 144 (Supplement 1): 6505.
https://doi.org/10.1182/blood-2024-208356
Published: 2024
Journal Articles

ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Jason R. Westin, Alex F. Herrera, Ryan Lynch, Jeremy S. Abramson, Don A. Stevens, Matthew Matasar, Lindsey Fitzgerald, Alan P Skarbnik, Chaitanya Iragavarapu, James H Essell, Bradley D. Hunter, Akil Merchant, Indumathy Varadarajan, Anand Tandra, Edward Licitra, Locke Johnson Bryan, Rushang D. Patel, Rajesh Behl, Jeff P. Sharman, Houston Holmes, Habte A. Yimer, Mitul Gandhi, Nosha Farhadfar, Nancy L. Bartlett, Michael Leukam, Tahir Latif, Paolo Caimi, Jean Yared, Amy Feng, Lynn Navale, Sri Ghatta, John B. Le Gall, Zachary J Roberts, John M. Burke
Journal: Blood
Blood (2024) 144 (Supplement 1): 3132.1.
https://doi.org/10.1182/blood-2024-194909
Published: 2024
Journal Articles

Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States

Matthew Matasar, Katherine L Rosettie, Almut Mecke, Danilo Di Maio, Shih-Wen Lin, Mei Wu, Esprit Ma
Journal: Blood
Blood (2024) 144 (Supplement 1): 3648.
https://doi.org/10.1182/blood-2024-198657
Published: 2024
Journal Articles

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

L. Elizabeth Budde, Matthew Matasar, Laurie H. Sehn, Sarit E. Assouline, John Kuruvilla, Ian W. Flinn, Sung-Soo Yoon, Francesc Bosch, Daniel Greenwald, Norma C. Gutierrez, Dimitrios Tzachanis, Paula Marlton, Delaney McGuirt, Shen Yin, Michael C. Wei, Antonia Kwan, Samuel Tracy, Elicia Penuel, Nancy L. Bartlett
Journal: Blood
Blood (2024) 144 (Supplement 1): 1646.
https://doi.org/10.1182/blood-2024-197902
Published: 2024
Journal Articles

Practice Patterns Inform Patient-Centered Approaches for the Integration of BTK Inhibitors in Frontline Mantle Cell Lymphoma

Tisheeka Graham, Tariqa Ackbarali, Anita Kumar, Matthew Matasar
Journal: Blood
Blood (2024) 144 (Supplement 1): 7785.
https://doi.org/10.1182/blood-2024-208930
Published: 2024
Journal Articles

Communicating with Patients While Navigating the New Landscape of Diffuse Large B-Cell Lymphoma (DLBCL)

Lilly Meier, Elizabeth Budde, Liffy Indu Cherian, Matthew Matasar, Amitkumar Mehta, Nilanjan Ghosh, Ashley Lile, Elana Plotkin, Nicole A Colwell, Molly Kisiel
Journal: Blood
Blood (2024) 144 (Supplement 1): 7945.
https://doi.org/10.1182/blood-2024-194129
Published: 2024
Journal Articles

Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

Matthew J. Cortese, MD, MPH, Megan M Herr, Nisha Nair, Jason Romancik, Natalie Grover, Rahul S Bhansali, Colin Thomas, Tamara K Moyo, Vaishalee P Kenkre, Thomas Ollila, Brian Hess, Lindsey Fitzgerald, Geoffrey Shouse, Matthew Matasar, Kaitlin Annunzio, James A Davis, Christy Jesme, Ari Pelcovits, Megan Melody, Jonathan Moreira, Adam Yuh Lin, Shuo Ma, Jane N Winter, Alex Niu, Alexey V. Danilov, Nirav N. Shah, Deborah M. Stephens, Jonathon B. Cohen, Leo I. Gordon, Stefan K. Barta, Narendranath Epperla, Reem Karmali
Journal: Blood
Blood (2024) 144 (Supplement 1): 525.
https://doi.org/10.1182/blood-2024-212106
Published: 2024
Journal Articles

A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study

Vaishalee P Kenkre, Yong Lin, Narendranath Epperla, Saurabh A Rajguru, Julie E Chang, Priyanka A. Pophali, Elyse I Harris, Christopher D Fletcher, Matthew Matasar, Hussam Eltoukhy, David A. Bond, Yazeed Sawalha, Beth Christian, Timothy Voorhees, Mariah Endres, Mitch Howard, Damayanti Bhavsar, Misty Fleming, Jordan S. Carter, Andrew M Evens
Journal: Blood
Blood (2024) 144 (Supplement 1): 4415.
https://doi.org/10.1182/blood-2024-202639
Published: 2024
Journal Articles

Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T-Naive and CAR-T-Exposed Patients

Sameh Gaballa, Jing-Zhou Hou, Sumana Devata, Seok-Goo Cho, Ranjit Nair, Dok Hyun Yoon, Ryan Jacobs, Koji Izutsu, Don A. Stevens, Dai Maruyama, Constantine S. Tam, Yazeed Sawalha, Aravind Ramakrishnan, Matthew Matasar, Denise Brennan, Sue Zhu, Robin Lesley, Yasuhiro Oki, David Sermer, Tae Min Kim
Journal: Blood
Blood (2024) 144 (Supplement 1): 868.
https://doi.org/10.1182/blood-2024-193681
Published: 2024
Journal Articles

Evaluation of Baseline CAR-Hematotox Scores to Predict Increased Severe Infection Risk in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Odronextamab

Matthew Matasar, David Tucker, Tae Min Kim, Stefano Luminari, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry
Journal: Blood
Blood (2024) 144 (Supplement 1): 1650.
https://doi.org/10.1182/blood-2024-200166
Published: 2024
Journal Articles

Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study

Matthew Matasar, Max S. Topp, John N. Allan, Stephen M. Ansell, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi Mazza, Jingxian Cai, Julia Zecchini, Min Zhu, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Jennifer L. Crombie
Journal: Blood
Blood (2024) 144 (Supplement 1): 866.
https://doi.org/10.1182/blood-2024-199155
Published: 2024
Journal Articles

Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma

Raphael Steiner, Liana Nikolaenko, Swetha Kambhampati, Niloufer Khan, Ranjit Nair, Jeremy S. Abramson, Steven Horwitz, Matthew Matasar, Colette Owens, Ildefonso Ismael Rodriguez Rivera, David J. Straus, Timothy S Pardee, Sanjeev Luther, Win Su Thet, Shreya Vemuri, Ariela Noy
Journal: Blood
Blood (2024) 144 (Supplement 1): 1729.
https://doi.org/10.1182/blood-2024-202459
Published: 2024
Journal Articles

Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy

Brandon L Ellsworth, Megan Melody, Narendranath Epperla, Natalie Grover, Jason T Romancik, Matthew J Cortese, Rahul S Bhansali, Tamara K Moyo, Vaishalee P Kenkre, Thomas Ollila, Brian Hess, Lindsey Fitzgerald, Geoffrey Shouse, Matthew Matasar, Kaitlin Annunzio, Megan M Herr, James A Davis, Christy Jesme, Ari Pelcovits, Jonathan Moreira, Adam Yuh Lin, Shuo Ma, Jane N Winter, Alexey V. Danilov, Nirav N. Shah, Stefan K. Barta, Jonathon B Cohen, Leo I. Gordon, Deborah M. Stephens, Reem Karmali
Journal: Blood
Blood (2024) 144 (Supplement 1): 612.
https://doi.org/10.1182/blood-2024-202665
Published: 2024
Journal Articles

Rituximab +/- Ibrutinib As First Line Therapy for Marginal Zone Lymphoma

Ariela Noy, Win Su Thet, Shreya Vemuri, Venkatraman Seshan, Connie Lee Batlevi, Zachary D. Epstein-Peterson, Lorenzo Falchi, Paola Ghione, Thomas M. Habermann, Paul A. Hamlin, Erel Joffe, Jennifer Kimberly Lue, Matthew Matasar, Maria Lia Palomba, Andrew D. Zelenetz, Gilles Salles
Journal: Blood
Blood (2024) 144 (Supplement 1): 6352.
https://doi.org/10.1182/blood-2024-211730
Published: 2024
Journal Articles

Assessing the Impact of Digital Education on the Clinical Management of Rare Hematologic Malignancies

Tisheeka Graham, Tariqa Ackbarali, Katie Kowalski, Sharon M. Castellino, Lisa Giulino Roth, Matthew J. Ehrhardt, Matthew Matasar
Journal: Blood
Blood (2024) 144 (Supplement 1): 7794.
https://doi.org/10.1182/blood-2024-211680
Published: 2024
Journal Articles

Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study

Adam J. Olszewski, Matthew Matasar, Scott F Huntington, Thomas Ollila, Ari Pelcovits, Yun Kyoung Tiger, John L. Reagan, Anna Dorota Chorzalska, John Morgan, Makayla R Pardo, Jessica McMahon, Stephen Donnelly, Caylee Carmody, Jeannine Margolis, Charles Milrod, Patrycja M. Dubielecka
Journal: Blood
Blood (2024) 144 (Supplement 1): 1644.
https://doi.org/10.1182/blood-2024-193022
Published: 2024
Journal Articles

Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study

Mazyar Shadman, Nancy L. Bartlett, Matthew Matasar, Stephen J. Schuster, Sarit E. Assouline, Laurie H. Sehn, John Kuruvilla, Pratyush Giri, Chan Y. Cheah, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta Nastoupil, Michael C. Wei, Shen Yin, Connie Y. Ma, Samuel Tracy, Antonia Kwan, Elicia Penuel, L. Elizabeth Budde
Journal: Blood
Blood (2024) 144 (Supplement 1): 4407.
https://doi.org/10.1182/blood-2024-197897
Published: 2024
Journal Articles

Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Matthew Matasar, David Tucker, Tae Min Kim, Stefano Luminari, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry
Journal: Blood
Blood (2024) 144 (Supplement 1): 3076.
https://doi.org/10.1182/blood-2024-200259
Published: 2024
Journal Articles

Lower Total Cost of Care with Mosunetuzumab Compared with Alternative Novel Treatment Options in Third-Line or Later Relapsed/Refractory Follicular Lymphoma: A United States Third-Party Payer Perspective

Matthew Matasar, Katherine L Rosettie, Shih-Wen Lin, Mei Wu, Esprit Ma
Journal: Blood
Blood (2024) 144 (Supplement 1): 5029.
https://doi.org/10.1182/blood-2024-198660
Published: 2024
Journal Articles

Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Jie Wang, Jihao Zhou, Yucai Wang, Javier L. Munoz, Kevin G. Shim, Muhamad Alhaj Moustafa, Firas Baidoun, Kaitlin Annunzio, Narendranath Epperla, Michael McLane, Yasmin H. Karimi, Binh Luu, Stephen E Spurgeon, Cheryl Chang, Zihan Wan, Diamone Gathers, Emily R. King, Marcus P. Watkins, Nancy L. Bartlett, Christine E. Ryan, Genevieve M Gerhard, Philippe Armand, Ann S. LaCasce, Vedha Vaddaraju, Danielle S Wallace, Vaishalee P Kenkre, Chase Junge, Natalie Grover, Jorge A Florindez, Reem Karmali, Alexander V. Stanisic, Chen Zhang, Parameswaran Venugopal, Grace Ying, Caitlin Gribbin, Jia Ruan, Navika D Shukla, Sonali M. Smith, Viktoriya Zelikson, Michael E. Williams, Stefan K. Barta, Omar Elghawy, Jake Schade, Rohini Navalekar, Matthew Matasar, Andrew M Evens, Alexey V. Danilov, Timothy S. Fenske
Journal: Blood
Blood (2024) 144 (Supplement 1): 4406.
https://doi.org/10.1182/blood-2024-194601
Published: 2024